- Home
- SPRO vs RAPT Comparison
SPRO vs RAPT Comparison
Compare SPRO & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- RAPT
- Stock Information
- Founded
- SPRO 2013
- RAPT 2015
- Country
- SPRO United States
- RAPT United States
- Employees
- SPRO N/A
- RAPT N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- RAPT Health Care
- Exchange
- SPRO Nasdaq
- RAPT Nasdaq
- Market Cap
- SPRO 62.7M
- RAPT 65.6M
- IPO Year
- SPRO 2017
- RAPT 2019
- Fundamental
- Price
- SPRO $1.17
- RAPT $1.08
- Analyst Decision
- SPRO Buy
- RAPT Hold
- Analyst Count
- SPRO 3
- RAPT 10
- Target Price
- SPRO $5.00
- RAPT $5.00
- AVG Volume (30 Days)
- SPRO 470.6K
- RAPT 1.1M
- Earning Date
- SPRO 11-14-2024
- RAPT 11-12-2024
- Dividend Yield
- SPRO N/A
- RAPT N/A
- EPS Growth
- SPRO N/A
- RAPT N/A
- EPS
- SPRO 0.06
- RAPT N/A
- Revenue
- SPRO $106,455,000.00
- RAPT N/A
- Revenue This Year
- SPRO N/A
- RAPT N/A
- Revenue Next Year
- SPRO N/A
- RAPT N/A
- P/E Ratio
- SPRO $17.92
- RAPT N/A
- Revenue Growth
- SPRO 37.01
- RAPT N/A
- 52 Week Low
- SPRO $1.01
- RAPT $1.00
- 52 Week High
- SPRO $1.89
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- SPRO 41.49
- RAPT 33.76
- Support Level
- SPRO $1.28
- RAPT $1.00
- Resistance Level
- SPRO $1.22
- RAPT $1.96
- Average True Range (ATR)
- SPRO 0.07
- RAPT 0.32
- MACD
- SPRO -0.01
- RAPT -0.12
- Stochastic Oscillator
- SPRO 32.73
- RAPT 3.45
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.